Panacea Biotec debuts EasyFourPol fully-liquid wP-IPV pentavalent vaccine in India
Panacea Biotec, one of India’s leading biotechnology companies, is proud to announce two major developments: the launch of the world’s first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol, in India and the registration of Valganciclovir 50 mg/ml Powder for Oral Solution in Germany by its subsidiary, Panacea Biotec Germany GmbH.
EasyFourPol is a milestone in paediatric vaccination, offering protection against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. This ready-to-use combination vaccine simplifies the vaccination process by eliminating the need for preparation by healthcare workers at clinics. It provides the same level of protection as single-antigen vaccines, reduces the number of visits to vaccination centers, and lowers the overall cost of immunization for all stakeholders. Fewer shots also translate to more efficiency at vaccination points and reduced carbon emissions.
Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, expressed his delight at the launch of EasyFourPol, highlighting its significance in the company’s innovative vaccine portfolio. “This launch is another landmark in our journey to make vaccinations easier and more accessible while supporting the UN Sustainable Development Goals,” he stated.
Innovation in Vaccination: Panacea Biotec Introduces EasyFourPol Vaccine
In addition to the launch in India, Panacea Biotec Germany GmbH is excited to announce the registration of Valganciclovir 50 mg/ml Powder for Oral Solution in Germany. Competing in a €1 million market, this medication is an important addition to the company’s transplant care portfolio. Valganciclovir is used for the treatment of cytomegalovirus (CMV) retinitis in adult patients with AIDS and the prophylaxis of CMV disease in organ transplant recipients.
Panacea Biotec, with its innovative approaches in both India and Germany, continues to focus on broadening its therapeutic offerings. The company’s commitment to developing high-quality and sustainable medicines for transplant care is reflected in its latest addition to the German market.
These significant achievements by Panacea Biotec represent a substantial advancement in global healthcare, showcasing the company’s dedication to delivering innovative healthcare solutions that meet the growing needs of patients worldwide.